Free Trial
NASDAQ:WVE

WAVE Life Sciences (WVE) Stock Price, News & Analysis

WAVE Life Sciences logo
$10.08 +0.11 (+1.10%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$10.14 +0.06 (+0.64%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About WAVE Life Sciences Stock (NASDAQ:WVE)

Key Stats

Today's Range
$9.87
$10.42
50-Day Range
$6.50
$10.15
52-Week Range
$5.04
$16.74
Volume
1.51 million shs
Average Volume
1.69 million shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.27
Consensus Rating
Moderate Buy

Company Overview

WAVE Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

WVE MarketRank™: 

WAVE Life Sciences scored higher than 95% of companies evaluated by MarketBeat, and ranked 49th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    WAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    WAVE Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about WAVE Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for WAVE Life Sciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of WAVE Life Sciences is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of WAVE Life Sciences is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    WAVE Life Sciences has a P/B Ratio of 11.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about WAVE Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.29% of the float of WAVE Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    WAVE Life Sciences has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in WAVE Life Sciences has recently decreased by 2.01%, indicating that investor sentiment is improving.
  • Dividend Yield

    WAVE Life Sciences does not currently pay a dividend.

  • Dividend Growth

    WAVE Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.29% of the float of WAVE Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    WAVE Life Sciences has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in WAVE Life Sciences has recently decreased by 2.01%, indicating that investor sentiment is improving.
  • News Sentiment

    WAVE Life Sciences has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for WAVE Life Sciences this week, compared to 7 articles on an average week.
  • Search Interest

    11 people have searched for WVE on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,631,568.00 in company stock.

  • Percentage Held by Insiders

    23.98% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about WAVE Life Sciences' insider trading history.
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for WAVE Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WVE Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
See More Headlines

WVE Stock Analysis - Frequently Asked Questions

WAVE Life Sciences' stock was trading at $12.37 on January 1st, 2025. Since then, WVE stock has decreased by 18.5% and is now trading at $10.08.

WAVE Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings data on Wednesday, July, 30th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.02. The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $11.52 million.
Read the conference call transcript
.

WAVE Life Sciences' top institutional investors include Adage Capital Partners GP L.L.C. (9.44%), 683 Capital Management LLC (2.58%), Loomis Sayles & Co. L P (2.07%) and Emerald Advisers LLC (2.05%). Insiders that own company stock include Ra Capital Management, LP, Plc Gsk, Ken Takanashi, Gregory L Verdine, Paul Bolno, Chandra Vargeese, Christian O Henry, Kyle Moran and Chris Francis.
View institutional ownership trends
.

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX).

Company Calendar

Last Earnings
7/30/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:WVE
CIK
1631574
Employees
240
Year Founded
2012

Price Target and Rating

High Price Target
$36.00
Low Price Target
$10.00
Potential Upside/Downside
+101.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$97.01 million
Net Margins
N/A
Pretax Margin
-138.24%
Return on Equity
-78.45%
Return on Assets
-41.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.56
Quick Ratio
2.56

Sales & Book Value

Annual Sales
$108.30 million
Price / Sales
14.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.88 per share
Price / Book
11.45

Miscellaneous

Outstanding Shares
159,140,000
Free Float
120,978,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
-0.95

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:WVE) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners